Amiodarone-induced Hypothyroidism with EPO-resistant Anemia in a Patient with Chronic Renal Failure
Authors:
- Yee-Yung NgYNYee-Yung Ng
- 1 November 2008
- journal article
- case report
- Published by Wolters Kluwer Health in Journal of the Chinese Medical Association
- Vol. 71 (11) , 576-578
Abstract
The overall incidence of amiodarone-induced thyroid dysfunction ranges from 2% to 24%. One third to half of patients with hypothyroidism have anemia due to some decrease in normal red blood cell mass and erythropoietin (EPO) resistance. Therefore, for patients with chronic renal disease under medication with amiodarone, early regular thyroid function test should be checked in order to avoid amiodarone-induced hypothyroidism and EPO-resistant anemia. If amiodarone-induced hypothyroidism and EPO-resistant anemia occur in patients with chronic renal failure, early thyroxine should be given instead of waiting for spontaneous recovery by amiodarone discontinuation only. Here, we report a patient with chronic renal failure who developed EPO-resistant anemia after amiodarone treatment for arrhythmia. The hemoglobin level responded to EPO therapy rapidly after thyroxine administration and amiodarone discontinuationKeywords
This publication has 6 references indexed in Scilit:
- Chronic renal diseaseBMJ, 2002
- Iodine-Induced HypothyroidismThyroid®, 2001
- Amiodarone and the thyroid: a practical guide to the management of thyroid dysfunction induced by amiodarone therapyHeart, 1998
- Resistance to Erythropoietin: Immunohemolytic Anemia Induced by Residual Formaldehyde in DialyzersAmerican Journal of Kidney Diseases, 1993
- Environmental Iodine Intake and Thyroid Dysfunction During Chronic Amiodarone TherapyAnnals of Internal Medicine, 1984
- Anemia in Thyroid DiseasesMedical Clinics of North America, 1975